Bris­tol My­ers drops an­oth­er Cy­tomX pro­gram

Bris­tol My­ers Squibb dropped an­oth­er CT­LA-4 pro­gram from its decade-long re­search col­lab­o­ra­tion with Cy­tomX af­ter the big phar­ma re­viewed its port­fo­lio.

Cy­tomX an­nounced the change in its 2023 fi­nan­cial re­sults on Mon­day, not­ing that the com­pa­nies are still col­lab­o­rat­ing on mul­ti­ple pre­clin­i­cal pro­grams, in­clud­ing T cell en­gagers. It was no­ti­fied by BMS on March 6 that the an­ti-CT­LA-4, BMS-986288, won’t ad­vance be­yond its cur­rent tri­al. That Phase II study is in­ves­ti­gat­ing the drug as a monother­a­py and in com­bi­na­tion with nivolum­ab for pa­tients with ad­vanced sol­id tu­mors and is set to wrap up in April, ac­cord­ing to clin­i­cal­tri­als.gov.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER